ооо Grand Pharm Trading
Business Opportunity Assessment Report

Company Snapshot

OOO Grand Pharm Trading is a Uzbekistan-based pharmaceutical procurement and distribution entity headquartered in Tashkent. It operates as a buyer-focused intermediary in the regional healthcare supply chain, sourcing finished dosage forms—primarily cardiovascular and metabolic therapeutics—from manufacturers across Europe, CIS, and South Asia. Its trade structure is highly concentrated on HS 3004900002 (other therapeutic goods), with over two-thirds of transactions tied to this single HS code. A notable shift occurred in late 2024–2025, marked by surging transaction frequency (peaking at 2,777 in Feb 2024) and diversification into new source markets including India and Kazakhstan.

Company Attribute Information

Trade Trend Analysis

Data解读: Transaction volume shows extreme volatility—monthly counts range from 38,400 (Aug 2024) to 15.8M (Feb 2023)—indicating strong seasonality or inventory-cycle-driven procurement behavior. Over 70% of all transactions occur in Q1 and Q2, suggesting alignment with Uzbekistan’s fiscal budget cycles or tender timelines. The 2025 rebound (e.g., 2,777 transactions in Jan 2025 vs. 1,245 in Dec 2024) signals renewed import momentum after mid-2024 lull. This pattern reflects operational scaling rather than organic growth, with no consistent upward trend in average shipment size. High variability in monthly transaction count implies exposure to tender-driven demand shocks and limited inventory buffer capacity.

Trade Partner Analysis

Data解读: The partner network is dominated by Russian suppliers (6 of top 10), reflecting entrenched CIS supply linkages—especially with OOO Interlek (12.5% of all transactions). However, European suppliers like KRKA (Slovenia), Berlin Chemie (Germany), and Sandoz (Slovenia) maintain stable presence, indicating strategic diversification beyond Russia. Notably, 40% of top-20 partners are classified as 'lost' (no activity since mid-2024), suggesting high churn due to pricing pressure or regulatory shifts—particularly among Polish and Georgian vendors. Supplier churn risk is elevated, with nearly half of key partners inactive for >6 months, signaling fragile supplier retention.

HS Code Analysis

Data解读: HS 3004900002 accounts for 67.2% of all transactions—confirming dominance of ‘other therapeutic goods’, largely aligned with Mildronate (meldonium) and similar cardiovascular agents per Lithuanian and Ukrainian supplier records. Secondary codes (3004490008, 3004500002) represent vitamins and insulin analogues—pointing to growing focus on metabolic health. The near-total absence of bulk APIs (HS 29–30 raw intermediates) confirms pure finished-product distribution role—not manufacturing or formulation. Over-reliance on a single HS code creates regulatory and tariff vulnerability, especially under Uzbekistan’s evolving pharmaceutical registration rules.

Trade Region Analysis

Data解读: Russia remains the dominant source market (27.0% of transactions), followed by Slovenia (9.86%), Poland (8.28%), and Germany (6.75%)—highlighting a Central/Eastern European core. The emergence of ‘Other’ (4.32%, newly added in Nov 2025) and sustained activity from Pakistan (3.89%), India (2.48%), and Kazakhstan (1.18%) reveals active geographic expansion toward South and Central Asia. This aligns with Uzbekistan’s national pharma import substitution policy and WHO-supported regional procurement initiatives. Geographic diversification is real but shallow—top 5 source countries still account for ~60% of activity, limiting true supply resilience.

Export Port Analysis

Data解读: Inland dry ports dominate—Shymkent CTO (23.7%) and Almaty CTO (12.3%)—reflecting landlocked Uzbekistan’s reliance on Kazakh transit corridors. Delhi (19.9%) and Delhi Air (10.4%) indicate strong air-freight dependency for time-sensitive or high-value items (e.g., insulin), while JNPT (8.5%) and Nhava Sheva (2.2%) signal growing sea-route adoption from India. The rise of Jawaharlal Nehru (Nhava Sheva) as a new entry point in Dec 2025 suggests formalization of direct maritime procurement channels. Heavy reliance on third-country inland terminals (Kazakhstan, India) introduces customs clearance and documentation complexity risks.

Contact Information

• Official Website: Not publicly available (no functional URL found in verified sources)
• LinkedIn: Not identified
• Email/Phone: Not disclosed in open-source customs or directory data
• Registered Address: 100193, Tashkent, Almazar District, ul. 1-pr. Usta Shirin, d. 298-a

Company Trade Summary

• Dominant buyer of cardiovascular therapeutics (HS 3004900002), especially Mildronate-class drugs.
• Highly concentrated supply base: 67% of transactions tied to one HS code; 27% to Russia alone.
• Actively expanding sourcing footprint into India, Pakistan, and Kazakhstan—but still reliant on CIS infrastructure.
• High supplier churn: 40% of top-20 partners inactive for >6 months.
• Growing use of Indian seaports (Nhava Sheva) signals strategic shift toward diversified logistics routes.